To determine the changes in the cross-sectional area (CSA) of myofibers and their subtype distribution based on the myosin isoform expression after bupivacaine (BUP) injection in the EOM of rabbits and help the understanding of strabismus correction after BUP injection in the clinical practice. A total of 32 rabbits received 0.3 mL of 1.5% BUP in the superior rectus muscle (SR) of the right eye (OD) and were sacrificed at days 7, 28, 60, and 92. Additional eight untouched rabbits were included as controls. Hematoxylin and eosin staining was performed, and ImageJ software was used to measure CSA. Immunohistochemical analysis was performed to analyze the proportion of myofibers positive for myosin types 1 (slow), 2 (fast) and embryonic. Myofiber area measurement decreased 7 days after BUP injection [SR, 1271 ± 412 μm (control) to 909 ± 255 μm (day 7)] after BUP injection, followed by an increasing trend after 28 days and normalization after 92 days [SR; 1062 ± 363 μm (day 28), 1492 ± 404 μm (day 60), 1317 ± 334 μm (day 92)]. The proportion of slow myosin-positive fibers increased in the 60-day group (88.5% ± 16.2%). There was no statistically significant difference in fast myosin-positive fibers. The inferior rectus of both eyes showed an increase in CSA. No increase of endomysial fibrous tissue was observed after 60 and 92 days of BUP injection. Bupivacaine, when injected into the SR of rabbits, initially decreases the fiber area followed by a transient increasing trend and normalization. There is a transient increase in the proportion of slow myosin-positive fibers in the injected muscle. Muscle adaptation in untreated EOM was found with increased CSA. These findings help clarify the clinical effects of BUP in extraocular muscle.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exer.2018.03.004DOI Listing

Publication Analysis

Top Keywords

bup injection
20
myosin-positive fibers
12
days bup
8
increasing trend
8
proportion slow
8
slow myosin-positive
8
bup
7
muscle
5
injection
5
days
5

Similar Publications

Article Synopsis
  • The study is focused on the increasing issue of hospitalizations related to opioid use disorder (OUD), comparing standard addiction consultation services to a specific treatment involving a long-lasting buprenorphine injection to improve post-hospital care engagement.
  • Patients in six U.S. hospitals who were not on medication for OUD before admission will be randomly assigned either to continue usual care or receive a single dose of a 28-day extended-release buprenorphine upon discharge.
  • Outcomes will be assessed at multiple follow-up points, with the primary goal of seeing if the XR-BUP group shows higher engagement in ongoing treatment 34 days after leaving the hospital, while also monitoring for safety and various secondary effects.
View Article and Find Full Text PDF

Background And Objectives: Buprenorphine extended-release monthly formulation (BUP-XR, SUBLOCADE) is approved for treatment of moderate-to-severe opioid use disorder (OUD) following subcutaneous injection in the abdomen. This open-label pharmacokinetic study assessed three alternative injection locations (upper arm, thigh, buttocks) to offer additional flexibility considering the chronic nature of the disease and patient preferences.

Methods: Following stabilization on 12/3 mg/day of sublingual buprenorphine/naloxone for ≥ 7 days, participants with moderate-to-severe OUD were randomized to receive a single 300-mg BUP-XR injection in the upper arm, thigh, buttocks, or abdomen (reference).

View Article and Find Full Text PDF

Background: The aim of the current study is to identify the possible protective effect of bupropion (BUP) on liver injury in rat model of myocardial infarction (MI). BUP was administered in the presence and absence of MI.

Materials And Methods: Thirty-two Wistar adult male rats were randomly arranged into four groups: control, BUP (30 mg/kg/day, intraperitoneal) for 28 days, isoproterenol (ISO) was injected subcutaneous (85 mg/kg) in the 26th and 27th days and BUP/ISO groups.

View Article and Find Full Text PDF
Article Synopsis
  • The study focuses on the costs associated with providing medication-assisted treatment for opioid dependence using extended-release buprenorphine (BUP-XR) through a detailed bottom-up cost analysis.
  • Conducted in Australia, the research involved 100 participants receiving monthly BUP-XR injections, revealing an average annual treatment cost of $6,656 per client, with medication costs accounting for 95% of the monthly expense.
  • The findings suggest that investing in BUP-XR treatment could optimize health system resources, making this cost data valuable for evaluating its effectiveness compared to other opioid treatments.
View Article and Find Full Text PDF

Trends in injectable buprenorphine prescribing in Canada: A descriptive analysis in five Canadian Provinces.

Drug Alcohol Depend

November 2024

Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada; ICES, Toronto, Canada; Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, Canada; Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada. Electronic address:

Article Synopsis
  • Injectable extended-release buprenorphine (BUP-ER) was introduced in Canada in February 2020, offering a new option for opioid agonist therapy (OAT), and this study examines its uptake across five provinces until March 2022.
  • A total of 6,528 individuals received BUP-ER, mainly in British Columbia and Ontario, with usage rates highest in British Columbia (16.6 per 100,000 population) and lowest in Ontario (9.1 per 100,000).
  • The study found greater BUP-ER usage in rural areas compared to urban settings and noted significant variations in the number of prescribers per 100,000 population across provinces, indicating differing access to
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!